Selective biologics for ulcerative colitis and Crohn's disease – clinical utility of vedolizumab
Jill MV Petkau, Bertus Eksteen Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada Abstract: Inflammatory bowel disease (IBD) encompasses a cluster of different disease phenotypes which are broadly classified into ulcerative colitis and Croh...
Guardado en:
Autores principales: | Petkau JM, Eksteen B |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/16d54277c0ca45cd9a766de82cb513b8 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A Practical Guide to Therapeutic Drug Monitoring of Biologic Medications for Inflammatory Bowel Disease
por: Byron P. Vaughn
Publicado: (2021) -
Colitis de Crohn: resultados del tratamiento quirúrgico y evolución alejada
por: Imigo G.,Felipe, et al.
Publicado: (2018) -
Epidemiology of Inflammatory Bowel Diseases (IBD) in Iran: A review of 740 patients in Fars province, Southern Iran.
por: John F.Mayberry
Publicado: (2013) -
Melilotus officinalis L. Protects Ulcerative Colitis in Rats
por: Hajar Khazraei, et al.
Publicado: (2015) -
Indeterminate Colitis – Update on Treatment Options
por: Venkateswaran N, et al.
Publicado: (2021)